Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies.
Mitchell S DavisRiley K SpencerChandler E JohnsonKareem G ElhageJoy Q JinMarwa HakimiTina BhutaniWilson LiaoPublished in: Dermatology and therapy (2023)
Our findings indicate that the development of CTCL is rare in the setting of psoriasis biologic use. Of the limited number of cases of CTCL found, most were in the setting of TNF inhibitor use and no cases of CTCL were reported in the setting of IL-23 inhibitor use.
Keyphrases